Neoleukin Therapeutics, Inc. NLTX
3.49 0.00 (+0.00%)
At closeDec 18, 2023, 4:00 PM EST
3.42 Day range 3.59
52-week range unavailable
- Market cap
- 8.20M
- Shares out
- 2.35M
- Forward P/E
- -20.53
- Volume
- 109.09K
- Open
- 3.45
- Previous close
- 3.49
- Day's range
- 3.42 – 3.59
- Beta
- 1.10
- Analysts
- Hold
- Price target
- 1.50 (-57.0%)
- Earnings date
- Nov 14, 2023
2Y -21.26 (-85.90%)
Key statistics
- Enterprise value
- -35.02M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -19.73M
- Total cash
- 78.51M
- Total debt
- 10.69M
- Return on equity
- -37.88%
- Short % of float
- 0.28%
- 50-day average
- 13.83
- 200-day average
- 14.98
Analyst view
Consensus: hold
Hold
Price target (mean) 1.50
Ratings (-1m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 14, 2023
Expected Nov 14, 2023. Consensus EPS estimate 0.00.
Financials — quick view
NLTX Revenue — quarterly 0
NLTX Net income — quarterly -2.08M
NLTX EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2023 | Sep 1, 2023 | -0.80 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.75 | — | — | — |
| May 8, 2023 | Mar 1, 2023 | -0.90 | — | — | — |
| Mar 21, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -1.60 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | -1.50 | — | — | — |
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- neoleukin.com
News
Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast 
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX) 
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split 
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split 
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc 
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX 
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene 
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders 
Neurogene and Neoleukin Announce Definitive Merger Agreement 
Neoleukin Therapeutics: Strategic Review Play
Your note
Sign in to keep a note on NLTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 16, 2023 | 0 |
| DRACHMAN JONATHAN G | Chief Executive Officer | Stock Gift | Oct 25, 2021 | 2,398,690 |
| HO ROBERT | Chief Financial Officer | Sale | Mar 16, 2021 | 21,503 |
| LEVITT DANIEL J | Director | Sale | May 13, 2018 | 0 |
| MACKENZIE LLOYD | Chief Operating Officer | Sale | Mar 14, 2018 | 0 |
| MAIN DAVID J | Chief Executive Officer | Sale | Jun 4, 2017 | 71,530 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Brothers Advisors, LLC | 1.74% | 764,348 | 3.17M | Jun 29, 2023 |
| Lynx1 Capital Management Lp | 1.41% | 618,911 | 2.57M | Jun 29, 2023 |
| Redmile Group, LLC | 1.32% | 582,446 | 2.42M | Jun 29, 2023 |
| Bank of America Corporation | 0.53% | 232,004 | 962.82K | Jun 29, 2023 |
| Vanguard Group Inc | 0.46% | 202,162 | 838.97K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.43% | 187,445 | 777.90K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.22% | 95,768 | 397.44K | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 0.22% | 98,708 | 409.64K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.08% | 34,362 | 137.45K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.02% | 7,394 | 29.58K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.02% | 9,650 | 38.60K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 4,506 | 18.02K | May 30, 2023 |